IP Library Granted Patent US 9,006,290
Granted Patent B2
US 9,006,290 · App. 14/138,919 · Granted Apr 14, 2015

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

Inventors: Jean-Louis Henri Dasseux (Toulouse, FR); Carmen Daniela Oniciu (Toulouse, FR)
Assignee: Esperion Therapeutics, Inc.
C07C59/245C07C31/20C07C31/22C07C31/24C07C59/11C07C59/285C07C59/29C07C59/46C07C59/48C07C59/54C07C62/02C07C62/06C07C65/17C07C69/757C07D213/80C07D309/10C07D309/12C07D405/12C07F9/093C07F9/094C07F9/117C07F9/2425C07F9/4423C07C2101/02C07C2101/04C07C2101/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,006,290
App. No.
14/138,919
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (19)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein;

m is 0;

each occurrence of n is independently an integer ranging from 3 to 7;

X is(CH 2 )z, wherein z is 0;

R 1 and R 2 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 ) cycloakyl group;

R 11 and R 12 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 ) cycloakyl group;

each occurrence of Y 1 and Y 2 is independently COOH or COOR 3 ; and

R 3 is (C 1 -C 6 )akyl.

2. The compound of claim 1 , wherein n is 5.

3. The compound of claim 2 , wherein Y 1 and Y 2 are COOH.

4. A compound having the following structure:

5. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle.

7. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable vehicle.

8. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable vehicle.

9. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable vehicle.

10. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable vehicle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2014
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033943/0743 →
MERGER Recorded Oct 14, 2014
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033946/0330 →
Continuity (8)
Continuation 13650852 · Oct 12, 2012
Continuation 13414855 · Mar 8, 2012
Continuation 13270297 · Oct 11, 2011
Continuation 12135504 · Jun 9, 2008
Continuation 11426380 · Jun 26, 2006
Division 10743287 · Dec 23, 2003
Provisional Application 60441795 · Jan 23, 2003
Related Publication 20140235723A1 · Aug 21, 2014